PT3773558T - Tratamento combinado de doença artrítica - Google Patents
Tratamento combinado de doença artríticaInfo
- Publication number
- PT3773558T PT3773558T PT207231416T PT20723141T PT3773558T PT 3773558 T PT3773558 T PT 3773558T PT 207231416 T PT207231416 T PT 207231416T PT 20723141 T PT20723141 T PT 20723141T PT 3773558 T PT3773558 T PT 3773558T
- Authority
- PT
- Portugal
- Prior art keywords
- combined treatment
- arthritic disease
- arthritic
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19173734 | 2019-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3773558T true PT3773558T (pt) | 2022-09-13 |
Family
ID=66483881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207231416T PT3773558T (pt) | 2019-05-10 | 2020-05-07 | Tratamento combinado de doença artrítica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12303489B2 (pt) |
| EP (2) | EP3773558B1 (pt) |
| JP (1) | JP7546599B2 (pt) |
| KR (1) | KR20220006551A (pt) |
| CN (1) | CN113795250B (pt) |
| AU (1) | AU2020273479B2 (pt) |
| BR (1) | BR112021022397A2 (pt) |
| CA (1) | CA3139000A1 (pt) |
| DK (1) | DK3773558T3 (pt) |
| ES (2) | ES3041907T3 (pt) |
| HU (1) | HUE059638T2 (pt) |
| IL (1) | IL287904B1 (pt) |
| LT (1) | LT3773558T (pt) |
| MX (1) | MX2021013296A (pt) |
| PL (1) | PL3773558T3 (pt) |
| PT (1) | PT3773558T (pt) |
| SG (1) | SG11202111821SA (pt) |
| SI (1) | SI3773558T1 (pt) |
| WO (1) | WO2020229297A1 (pt) |
| ZA (1) | ZA202108219B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3773558T1 (sl) | 2019-05-10 | 2022-11-30 | Synact Pharma Aps | Kombinirano zdravljenje artritične bolezni |
| BR112022018827A2 (pt) * | 2020-03-31 | 2022-11-22 | Synact Pharma Aps | Tratamento de doenças virais sintomáticas |
| EP4326247A1 (en) | 2021-04-23 | 2024-02-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Citraconic acid and derivatives thereof for use as a medicament |
| CA3220753A1 (en) | 2021-06-21 | 2022-12-29 | Synact Pharma Aps | Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salts |
| EP4440572A1 (en) * | 2021-11-29 | 2024-10-09 | SynAct Pharma ApS | Treatment of rheumatoid arthritis |
| EP4522160A1 (en) * | 2022-05-12 | 2025-03-19 | SynAct Pharma ApS | Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis |
| WO2024133643A1 (en) * | 2022-12-21 | 2024-06-27 | Synact Pharma Aps | Polymorph of phenyl pyrrole hydrazine carboximidamide compound |
| WO2025124760A1 (en) | 2023-12-11 | 2025-06-19 | Synact Pharma Aps | Treatment of subpopulation of patients with rheumatoid arthritis |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604348D0 (sv) | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
| WO1999021571A1 (en) | 1997-10-27 | 1999-05-06 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| TR200102765T2 (tr) | 1999-03-29 | 2002-05-21 | The Procter & Gamble Company | Melanokortin reseptör ligandları |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| WO2001005401A1 (en) | 1999-07-16 | 2001-01-25 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| CA2385592C (en) | 1999-09-17 | 2011-01-11 | Bing-Yan Zhu | Benzamides and related inhibitors of factor xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| CA2385589A1 (en) | 1999-09-17 | 2001-03-22 | Bing-Yan Zhu | Inhibitors of factor xa |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| EP1254114A2 (en) | 2000-01-28 | 2002-11-06 | Melacure Therapeutics AB | Melanocortin receptor agonists and antagonists |
| AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
| KR100440370B1 (ko) | 2000-04-01 | 2004-07-19 | (주)명문엘씨 | 2중 사출에 의한 밀폐용기 뚜껑 |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| CA2439691A1 (en) | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| CA2363528A1 (en) | 2001-11-19 | 2003-05-19 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Immediate release tablet containing naproxen sodium |
| GB2398299A (en) | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| MX2008015454A (es) * | 2006-06-09 | 2009-01-30 | Action Pharma As | Derivados de fenil-pirrol-aminoguanidina. |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| EP2045250A1 (en) | 2007-09-26 | 2009-04-08 | Action Pharma A/S | Ring-substituted phenyl pyrrole aminoguanidine derivatives |
| WO2009071101A1 (en) | 2007-12-07 | 2009-06-11 | Action Pharma A/S | N-modified aminoguanidine derivatives |
| WO2009074157A1 (en) | 2007-12-13 | 2009-06-18 | Action Pharma A/S | Fully-modified phenyl pyrrole aminoguanidines |
| US10387927B2 (en) | 2010-01-15 | 2019-08-20 | Dell Products L.P. | System and method for entitling digital assets |
| JP2011190199A (ja) * | 2010-03-12 | 2011-09-29 | Hideto Nakamura | 関節リウマチ薬 |
| US9662807B2 (en) | 2011-12-21 | 2017-05-30 | GKN Aerospace Services Structures, Corp. | Method for forming a fabric preform for a composite material by separately tensioning tows |
| PL2722340T3 (pl) | 2012-10-19 | 2015-08-31 | Txp Pharma Gmbh | Analogi alfa- i gamma-msh |
| EA034963B1 (ru) * | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Способ лечения расстройства заднего сегмента глаза |
| US9917808B2 (en) | 2013-03-14 | 2018-03-13 | International Business Machines Corporation | Grouping electronic messages |
| WO2015162483A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| WO2015162486A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues |
| PL3743064T3 (pl) | 2018-06-22 | 2022-01-10 | Synact Pharma Aps | Leczenie proteinurii |
| WO2020107221A1 (en) | 2018-11-27 | 2020-06-04 | Tsinghua University | Chemical activators of nicotinamide mononucleotide adenlyly transferase 2 (nmnat2) and uses thereof |
| SI3773558T1 (sl) | 2019-05-10 | 2022-11-30 | Synact Pharma Aps | Kombinirano zdravljenje artritične bolezni |
| CN113730797B (zh) | 2020-05-29 | 2023-05-16 | 创领心律管理医疗器械（上海）有限公司 | 电极板及可穿戴式除颤设备 |
-
2020
- 2020-05-07 SI SI202030094T patent/SI3773558T1/sl unknown
- 2020-05-07 CA CA3139000A patent/CA3139000A1/en active Pending
- 2020-05-07 MX MX2021013296A patent/MX2021013296A/es unknown
- 2020-05-07 PL PL20723141.6T patent/PL3773558T3/pl unknown
- 2020-05-07 JP JP2021566199A patent/JP7546599B2/ja active Active
- 2020-05-07 PT PT207231416T patent/PT3773558T/pt unknown
- 2020-05-07 WO PCT/EP2020/062711 patent/WO2020229297A1/en not_active Ceased
- 2020-05-07 EP EP20723141.6A patent/EP3773558B1/en active Active
- 2020-05-07 CN CN202080034595.6A patent/CN113795250B/zh active Active
- 2020-05-07 EP EP22178594.2A patent/EP4119140B1/en active Active
- 2020-05-07 HU HUE20723141A patent/HUE059638T2/hu unknown
- 2020-05-07 AU AU2020273479A patent/AU2020273479B2/en active Active
- 2020-05-07 ES ES22178594T patent/ES3041907T3/es active Active
- 2020-05-07 KR KR1020217038762A patent/KR20220006551A/ko active Pending
- 2020-05-07 DK DK20723141.6T patent/DK3773558T3/da active
- 2020-05-07 LT LTEPPCT/EP2020/062711T patent/LT3773558T/lt unknown
- 2020-05-07 US US17/609,849 patent/US12303489B2/en active Active
- 2020-05-07 ES ES20723141T patent/ES2927294T3/es active Active
- 2020-05-07 SG SG11202111821SA patent/SG11202111821SA/en unknown
- 2020-05-07 BR BR112021022397A patent/BR112021022397A2/pt unknown
-
2021
- 2021-10-25 ZA ZA2021/08219A patent/ZA202108219B/en unknown
- 2021-11-08 IL IL287904A patent/IL287904B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12303489B2 (en) | 2025-05-20 |
| PL3773558T3 (pl) | 2022-10-03 |
| AU2020273479A1 (en) | 2021-12-23 |
| MX2021013296A (es) | 2021-12-15 |
| AU2020273479B2 (en) | 2025-02-27 |
| SG11202111821SA (en) | 2021-11-29 |
| EP4119140A1 (en) | 2023-01-18 |
| US20220211666A1 (en) | 2022-07-07 |
| ES3041907T3 (en) | 2025-11-17 |
| KR20220006551A (ko) | 2022-01-17 |
| ES2927294T3 (es) | 2022-11-04 |
| EP3773558B1 (en) | 2022-06-15 |
| CN113795250B (zh) | 2024-10-15 |
| EP3773558A1 (en) | 2021-02-17 |
| HUE059638T2 (hu) | 2022-12-28 |
| ZA202108219B (en) | 2023-03-29 |
| BR112021022397A2 (pt) | 2021-12-28 |
| JP7546599B2 (ja) | 2024-09-06 |
| WO2020229297A1 (en) | 2020-11-19 |
| IL287904B1 (en) | 2025-11-01 |
| DK3773558T3 (da) | 2022-09-19 |
| LT3773558T (lt) | 2022-09-12 |
| IL287904A (en) | 2022-01-01 |
| JP2022531906A (ja) | 2022-07-12 |
| SI3773558T1 (sl) | 2022-11-30 |
| EP4119140C0 (en) | 2025-06-25 |
| EP4119140B1 (en) | 2025-06-25 |
| CN113795250A (zh) | 2021-12-14 |
| CA3139000A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3773558T (pt) | Tratamento combinado de doença artrítica | |
| HUE060711T2 (hu) | Makrociklusos vegyületek betegségek kezelésére | |
| EP3813808A4 (en) | Methods of treating substance abuse | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| IL285771A (en) | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator | |
| EP3351188A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
| EP3351186A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
| EP3351187A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
| IL269735A (en) | Antisense oligonucleotides for the treatment of stargardt disease | |
| HUE060517T2 (hu) | Immunhiányos betegség kezelésére szolgáló eljárások | |
| EP4076217A4 (en) | SYNDESMOSIS TREATMENT CONSTRUCT | |
| EP3669791A4 (en) | MEDICAL PLIERS | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| IL270552A (en) | Volclospoin composition for treating proteinuric kidney disease | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| EP3873528A4 (en) | Rasopathy treatment | |
| IL280968A (en) | Combination therapy | |
| EP4117655A4 (en) | Treatment methods | |
| PL3458067T3 (pl) | Leczenie chorób neurologicznych | |
| EP3856207A4 (en) | TREATMENT PROCESSES | |
| EP4405465A4 (en) | TREATMENT METHODS | |
| EP3630185A4 (en) | Treatment of neuroinflammatory disease | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| EP4024114C0 (en) | ENDOSCOPE | |
| LT3322438T (lt) | Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui |